Zhendong Lu, Siyun Fu, Wei Li, Xiang Gao, Jinghui Wang
{"title":"Prognostic role of C-reactive protein to albumin ratio in lung cancer: An updated systematic review and meta-analysis","authors":"Zhendong Lu, Siyun Fu, Wei Li, Xiang Gao, Jinghui Wang","doi":"10.1002/cdt3.91","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>C-reactive protein to albumin ratio (CRP/Alb ratio, CAR) has been suggested as a potential prognostic biomarker in lung cancer. This updated systematic review and meta-analysis aimed to assess the association between CAR and lung cancer prognosis in current literature.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic search of databases was conducted to identify relevant studies published up to April 2023. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association between CAR and overall survival (OS) and progression-free survival (PFS) and recurrence-free survival (RF) in lung cancer patients.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>This meta-analysis includes 16 studies with a total of 5337 patients, indicating a significant association between higher CAR and poorer OS, PFS, and RFS in lung cancer patients, with a pooled HR of 1.78 (95% CI = 1.60–1.99), 1.57 (95% CI = 1.36–1.80), and 1.97 (95% CI = 1.40–2.77), respectively.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This updated meta-analysis provides evidence for the potential prognostic role of CAR in lung cancer, suggesting its utility as an effective and noninvasive biomarker for identifying high-risk patients and informing treatment decisions in a cost-effective manner. However, further large-scale studies will be necessary to establish the optimal cut-off value for CAR in lung cancer and confirm the present findings.</p>\n </section>\n </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.91","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chronic Diseases and Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cdt3.91","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Background
C-reactive protein to albumin ratio (CRP/Alb ratio, CAR) has been suggested as a potential prognostic biomarker in lung cancer. This updated systematic review and meta-analysis aimed to assess the association between CAR and lung cancer prognosis in current literature.
Methods
A systematic search of databases was conducted to identify relevant studies published up to April 2023. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association between CAR and overall survival (OS) and progression-free survival (PFS) and recurrence-free survival (RF) in lung cancer patients.
Results
This meta-analysis includes 16 studies with a total of 5337 patients, indicating a significant association between higher CAR and poorer OS, PFS, and RFS in lung cancer patients, with a pooled HR of 1.78 (95% CI = 1.60–1.99), 1.57 (95% CI = 1.36–1.80), and 1.97 (95% CI = 1.40–2.77), respectively.
Conclusions
This updated meta-analysis provides evidence for the potential prognostic role of CAR in lung cancer, suggesting its utility as an effective and noninvasive biomarker for identifying high-risk patients and informing treatment decisions in a cost-effective manner. However, further large-scale studies will be necessary to establish the optimal cut-off value for CAR in lung cancer and confirm the present findings.
C反应蛋白与白蛋白比值(CRP/Alb ratio, CAR)已被认为是肺癌的潜在预后生物标志物。本最新的系统综述和荟萃分析旨在评估当前文献中CAR与肺癌预后之间的关系。系统检索数据库，确定截至2023年4月发表的相关研究。计算合并风险比(hr)和95%置信区间(CIs)，以评估肺癌患者CAR与总生存期(OS)、无进展生存期(PFS)和无复发生存期(RF)之间的关系。该荟萃分析包括16项研究，共5337例患者，表明肺癌患者较高的CAR与较差的OS、PFS和RFS之间存在显著关联，合并HR分别为1.78 (95% CI = 1.60-1.99)、1.57 (95% CI = 1.36-1.80)和1.97 (95% CI = 1.40-2.77)。这项最新的荟萃分析为CAR在肺癌中的潜在预后作用提供了证据，表明其作为一种有效且无创的生物标志物，可用于识别高风险患者，并以具有成本效益的方式为治疗决策提供信息。然而，需要进一步的大规模研究来确定CAR在肺癌中的最佳临界值，并证实目前的发现。
期刊介绍：
This journal aims to promote progress from basic research to clinical practice and to provide a forum for communication among basic, translational, and clinical research practitioners and physicians from all relevant disciplines. Chronic diseases such as cardiovascular diseases, cancer, diabetes, stroke, chronic respiratory diseases (such as asthma and COPD), chronic kidney diseases, and related translational research. Topics of interest for Chronic Diseases and Translational Medicine include Research and commentary on models of chronic diseases with significant implications for disease diagnosis and treatment Investigative studies of human biology with an emphasis on disease Perspectives and reviews on research topics that discuss the implications of findings from the viewpoints of basic science and clinical practic.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
